Sunflower Pharmaceutical announced that the company decided to use its own capital of RMB 10 million to invest in the establishment of a wholly-owned subsidiary, Sichuan Sunflower Pharmaceutical Co., Ltd., and the company holds 100% of the shares. The investment aims to promote the division and independent operation of each business segment of the marketing system and improve overall operational efficiency. This matter does not constitute a related transaction or major asset restructuring, and is within the authority of the board of directors, there is no need to submit it to the shareholders' meeting for consideration.

Zhitongcaijing · 4d ago
Sunflower Pharmaceutical announced that the company decided to use its own capital of RMB 10 million to invest in the establishment of a wholly-owned subsidiary, Sichuan Sunflower Pharmaceutical Co., Ltd., and the company holds 100% of the shares. The investment aims to promote the division and independent operation of each business segment of the marketing system and improve overall operational efficiency. This matter does not constitute a related transaction or major asset restructuring, and is within the authority of the board of directors, there is no need to submit it to the shareholders' meeting for consideration.